Aveanna Healthcare (AVAH) Financials

$7.28 -0.05 (-0.68%)

As of 04:00 PM Eastern

Annual Income Statements for Aveanna Healthcare

This table shows Aveanna Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2026
Period end date	12/28/2019	1/2/2021	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Net Income / (Loss) Attributable to Common Shareholders	-77	-57	-662	-135	-11	225
Consolidated Net Income / (Loss)	-77	-57	-662	-135	-11	225
Net Income / (Loss) Continuing Operations	-77	-57	-662	-135	-11	225
Total Pre-Tax Income	-75	-52	-664	-139	5.07	107
Total Operating Income	39	-3.49	-642	8.07	140	256
Total Gross Profit	419	455	553	595	636	810
Total Revenue	1,384	1,495	1,788	1,895	2,025	2,433
Operating Revenue	1,384	1,495	1,788	1,895	2,025	2,433
Total Cost of Revenue	965	1,041	1,234	1,300	1,389	1,623
Operating Cost of Revenue	965	1,041	1,234	1,300	1,389	1,623
Total Operating Expenses	380	458	1,196	587	496	554
Selling, General & Admin Expense	228	241	357	361	353	374
Depreciation Expense	14	17	21	14	11	11
Other Operating Expenses / (Income)	116	115	142	107	131	165
Restructuring Charge	23	9.56	0.10	0.47	1.49	3.81
Total Other Income / (Expense), net	-114	-48	-22	-147	-135	-150
Interest Expense	97	83	108	153	157	146
Interest & Investment Income	0.21	0.35	0.68	0.33	0.50	2.83
Other Income / (Expense), net	-17	34	86	5.85	21	-6.40
Income Tax Expense	1.49	5.32	-1.78	-4.47	16	-118
Basic Earnings per Share	($0.56)	($0.40)	($3.57)	($0.71)	($0.06)	$1.11
Weighted Average Basic Shares Outstanding	136.91M	140.97M	185.55M	189.96M	192.89M	203.53M
Diluted Earnings per Share	($0.56)	($0.40)	($3.57)	($0.71)	($0.06)	$1.05
Weighted Average Diluted Shares Outstanding	136.91M	140.97M	185.55M	189.96M	192.89M	214.98M
Weighted Average Basic & Diluted Shares Outstanding	136.91M	140.97M	185.86M	192.38M	195.09M	217.51M

This table shows Aveanna Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	4/4/2026
Net Income / (Loss) Attributable to Common Shareholders	26	-102	-26	-11	14	-43	29	5.19	27	14	42
Consolidated Net Income / (Loss)	26	-102	-26	-11	14	-43	29	5.19	27	14	42
Net Income / (Loss) Continuing Operations	26	-102	-26	-11	14	-43	29	5.19	27	14	42
Total Pre-Tax Income	25	-102	-32	1.49	3.98	-27	27	10	44	13	45
Total Operating Income	37	-76	29	23	37	34	46	52	80	54	69
Total Gross Profit	155	147	148	146	158	160	172	184	211	203	205
Total Revenue	472	478	479	491	505	509	520	559	590	622	648
Operating Revenue	472	478	479	491	505	509	520	559	590	622	648
Total Cost of Revenue	317	331	330	345	347	349	348	376	379	419	442
Operating Cost of Revenue	317	331	330	345	347	349	348	376	379	419	442
Total Operating Expenses	118	224	119	123	121	126	126	132	131	149	136
Selling, General & Admin Expense	91	91	87	88	88	88	89	91	90	95	96
Depreciation Expense	3.49	2.96	3.28	2.91	2.83	2.59	2.45	2.59	2.62	2.60	3.04
Other Operating Expenses / (Income)	23	24	29	32	30	35	33	38	35	52	34
Restructuring Charge	-0.03	0.43	-	0.00	0.00	0.15	1.34	0.11	3.40	-1.18	3.11
Total Other Income / (Expense), net	-13	-25	-61	-21	-33	-61	-19	-42	-36	-40	-24
Interest Expense	38	40	40	40	40	39	38	36	36	41	29
Interest & Investment Income	0.11	0.05	0.09	0.10	0.10	0.10	0.20	0.13	0.13	0.83	1.66
Other Income / (Expense), net	25	14	-21	18	6.37	-22	19	-5.45	-0.02	-0.00	3.15
Income Tax Expense	-0.81	0.63	-5.86	13	-9.93	16	-2.25	4.96	17	-0.65	3.32
Basic Earnings per Share	$0.14	($0.54)	($0.14)	($0.06)	$0.07	($0.22)	$0.15	$0.03	$0.13	$0.07	$0.19
Weighted Average Basic Shares Outstanding	189.07M	189.14M	189.96M	192.24M	192.60M	193.36M	192.89M	194.67M	200.97M	208.95M	214.60M
Diluted Earnings per Share	$0.13	($0.54)	($0.13)	($0.06)	$0.07	($0.22)	$0.15	$0.03	$0.13	$0.06	$0.19
Weighted Average Diluted Shares Outstanding	189.74M	189.14M	189.96M	192.24M	196.87M	193.36M	192.89M	206.24M	210.44M	222.23M	222.10M
Weighted Average Basic & Diluted Shares Outstanding	190.43M	190.73M	192.38M	192.38M	193.23M	193.23M	195.09M	195.09M	208.90M	208.91M	217.76M

This table details how cash moves in and out of Aveanna Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2026
Period end date	12/28/2019	1/2/2021	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Net Change in Cash & Equivalents	-4.67	134	-8.22	25	40	109
Net Cash From Operating Activities	-8.71	117	-48	23	33	126
Net Cash From Continuing Operating Activities	-8.71	117	-48	23	33	126
Net Income / (Loss) Continuing Operations	-77	-57	-662	-135	-11	225
Consolidated Net Income / (Loss)	-77	-57	-662	-135	-11	225
Depreciation Expense	14	17	21	14	11	11
Amortization Expense	6.72	7.53	25	5.18	5.46	5.85
Non-Cash Adjustments To Reconcile Net Income	35	99	609	161	56	80
Changes in Operating Assets and Liabilities, net	12	50	-42	-22	-29	-196
Net Cash From Investing Activities	-18	-194	-25	-8.79	-6.32	-22
Net Cash From Continuing Investing Activities	-18	-194	-25	-8.79	-6.32	-22
Purchase of Property, Plant & Equipment	-17	-15	-12	-6.12	-6.32	-7.45
Acquisitions	-0.96	-178	-2.01	-	0.00	-15
Net Cash From Financing Activities	22	211	62	11	14	5.41
Net Cash From Continuing Financing Activities	22	211	65	11	14	5.41
Repayment of Debt	17	120	-54	-75	-29	-7.38
Issuance of Debt	610	14	115	70	25	0.00
Issuance of Common Equity	0.00	50	4.02	0.95	3.09	6.31
Other Financing Activities, net	-606	29	0.73	15	15	6.48
Cash Interest Paid	93	73	103	138	153	143
Cash Income Taxes Paid	1.55	2.17	1.59	1.14	5.71	31

This table details how cash moves in and out of Aveanna Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	4/4/2026
Net Change in Cash & Equivalents	-6.42	20	-4.35	-1.34	5.05	31	5.83	-13	29	45	-3.99
Net Cash From Operating Activities	-11	29	-3.01	-12	1.81	29	13	-8.63	52	33	4.35
Net Cash From Continuing Operating Activities	-11	29	-3.01	-12	1.81	29	13	-8.63	52	33	4.35
Net Income / (Loss) Continuing Operations	26	-102	-26	-11	14	-43	29	5.19	27	14	42
Consolidated Net Income / (Loss)	26	-102	-26	-11	14	-43	29	5.19	27	14	42
Depreciation Expense	3.49	2.96	3.28	2.91	2.83	2.59	2.45	2.59	2.62	2.60	3.04
Amortization Expense	-2.94	14	-11	1.22	-4.97	1.31	1.66	1.65	1.70	1.49	0.97
Non-Cash Adjustments To Reconcile Net Income	-5.73	94	51	2.27	18	45	-1.93	27	16	22	9.38
Changes in Operating Assets and Liabilities, net	-31	20	-20	-7.20	-28	24	-18	-45	4.58	-6.86	-51
Net Cash From Investing Activities	-1.30	-1.13	-1.57	-1.31	-1.27	-2.21	-1.53	-2.35	-16	-2.02	-4.56
Net Cash From Continuing Investing Activities	-1.30	-1.13	-1.57	-1.31	-1.27	-2.21	-1.53	-2.35	-16	-2.02	-4.56
Purchase of Property, Plant & Equipment	-1.30	-1.13	-1.57	-1.31	-1.27	-2.21	-1.53	-2.35	-1.13	-2.02	-4.56
Acquisitions	-	-	-	-	-	-	-	0.00	-	-	0.00
Net Cash From Financing Activities	5.40	-7.29	0.22	12	4.51	3.62	-6.05	-1.81	-6.34	14	-3.78
Net Cash From Continuing Financing Activities	5.40	-7.29	0.22	12	4.51	3.62	-6.05	-1.81	-6.34	14	-3.78
Repayment of Debt	-9.23	-11	-9.83	-14	-4.75	-1.06	-9.79	-5.06	-4.74	-1,309	-5.72
Issuance of Debt	10	-	5.00	20	5.00	-	-	0.00	-	1,318	0.00
Issuance of Common Equity	0.95	-	-	1.35	-	1.74	0.00	1.79	-	2.15	0.00
Other Financing Activities, net	3.68	3.22	5.05	4.28	4.26	2.95	3.74	1.46	-1.61	3.03	1.94
Cash Interest Paid	36	39	39	38	39	38	38	35	34	44	28
Cash Income Taxes Paid	0.54	0.61	0.37	-0.06	5.00	0.71	0.07	-0.46	16	8.56	-0.01

This table presents Aveanna Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2026
Period end date	1/2/2021	1/2/2021	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Total Assets	1,844	1,844	1,712	1,613	1,663	2,012
Total Current Assets	341	341	270	315	393	560
Cash & Equivalents	137	137	19	44	84	193
Accounts Receivable	173	173	221	237	265	313
Prepaid Expenses	11	11	15	16	17	21
Other Current Assets	19	19	14	19	26	33
Plant, Property, & Equipment, net	33	33	23	21	17	17
Total Noncurrent Assets	1,471	1,471	1,419	1,278	1,253	1,435
Noncurrent Note & Lease Receivables	24	24	23	21	22	29
Goodwill	1,316	1,316	1,160	1,055	1,055	1,121
Intangible Assets	74	74	96	94	90	93
Noncurrent Deferred & Refundable Income Taxes	2.93	2.93	-	-	0.00	137
Other Noncurrent Operating Assets	54	54	141	108	87	56
Total Liabilities & Shareholders' Equity	1,844	1,844	1,712	1,613	1,663	2,012
Total Liabilities	1,577	1,577	1,716	1,740	1,785	1,817
Total Current Liabilities	260	260	326	355	402	424
Short-Term Debt	13	9.91	9.20	9.20	9.20	13
Accounts Payable	57	57	45	30	36	32
Accrued Expenses	57	57	44	67	88	108
Other Current Liabilities	107	112	229	248	269	271
Total Noncurrent Liabilities	1,319	1,319	1,392	1,388	1,385	1,393
Long-Term Debt	1,163	1,163	1,281	1,276	1,272	1,287
Asset Retirement Reserve & Litigation Obligation	54	54	58	62	67	78
Noncurrent Deferred & Payable Income Tax Liabilities	27	27	3.84	4.86	5.89	0.00
Other Noncurrent Operating Liabilities	73	73	48	45	40	29
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	265	265	-6.31	-130	-124	194
Total Preferred & Common Equity	265	265	-6.31	-130	-124	194
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	265	265	-6.31	-130	-124	194
Common Stock	723	723	1,230	1,242	1,259	1,352
Retained Earnings	-458	-458	-1,237	-1,371	-1,382	-1,157

This table presents Aveanna Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	10/1/2022	4/1/2023	7/1/2023	9/30/2023	3/30/2024	6/29/2024	9/28/2024	3/29/2025	6/28/2025	9/27/2025	4/4/2026
Total Assets	1,973	1,731	1,741	1,655	1,643	1,664	1,644	1,661	1,771	1,810	2,022
Total Current Assets	312	308	301	318	336	364	381	408	450	503	575
Cash & Equivalents	64	34	28	48	43	48	78	71	101	146	189
Accounts Receivable	219	242	237	236	258	273	265	295	316	313	333
Prepaid Expenses	13	17	16	12	16	17	12	20	18	14	24
Other Current Assets	17	16	20	22	20	27	25	21	15	29	30
Plant, Property, & Equipment, net	25	21	20	22	19	19	18	19	18	17	18
Total Noncurrent Assets	1,636	1,401	1,420	1,314	1,287	1,281	1,245	1,234	1,303	1,290	1,429
Noncurrent Note & Lease Receivables	24	24	27	23	25	24	26	18	21	22	30
Goodwill	1,368	1,160	1,160	1,055	1,055	1,055	1,055	1,055	1,119	1,116	1,121
Intangible Assets	98	98	97	95	93	93	90	89	94	94	92
Noncurrent Deferred & Refundable Income Taxes	0.00	-	-	-	-	-	-	-	-	-	137
Other Noncurrent Operating Assets	146	119	136	142	115	110	75	72	69	58	48
Total Liabilities & Shareholders' Equity	1,973	1,731	1,741	1,655	1,643	1,664	1,644	1,661	1,771	1,810	2,022
Total Liabilities	1,743	1,765	1,746	1,758	1,777	1,782	1,799	1,759	1,782	1,801	1,781
Total Current Liabilities	352	376	356	364	382	389	406	388	414	410	390
Short-Term Debt	9.20	9.20	9.20	9.20	9.20	9.20	9.20	9.20	9.20	13	13
Accounts Payable	49	43	38	37	43	39	42	30	47	27	34
Current Employee Benefit Liabilities	50	62	-	76	69	73	85	86	-	109	77
Other Current Liabilities	218	262	248	243	261	268	270	263	266	260	265
Total Noncurrent Liabilities	1,394	1,391	1,393	1,396	1,397	1,394	1,395	1,373	1,369	1,392	1,392
Long-Term Debt	1,283	1,280	1,279	1,278	1,275	1,274	1,275	1,271	1,269	1,289	1,284
Capital Lease Obligations	45	43	-	43	39	-	33	29	-	27	25
Asset Retirement Reserve & Litigation Obligation	61	61	64	67	72	24	73	64	63	68	82
Noncurrent Deferred & Payable Income Tax Liabilities	2.75	4.44	4.44	4.42	5.47	5.47	5.39	6.51	6.50	6.50	0.00
Other Noncurrent Operating Liabilities	2.75	2.45	45	4.04	5.94	91	7.31	2.26	29	1.53	0.73
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	228	-36	-6.74	-106	-136	-119	-156	-100	-12	9.18	240
Total Preferred & Common Equity	228	-36	-6.74	-106	-136	-119	-156	-100	-12	9.18	240
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	228	-36	-6.74	-106	-136	-119	-156	-100	-12	9.18	240
Common Stock	1,227	1,233	1,236	1,240	1,246	1,250	1,255	1,277	1,338	1,345	1,356
Retained Earnings	-999	-1,269	-1,243	-1,345	-1,382	-1,369	-1,411	-1,377	-1,350	-1,336	-1,115

This table displays calculated financial ratios and metrics derived from Aveanna Healthcare's official financial filings.

Metric	2020	2021	2022	2023	2024	2026
Period end date	12/28/2019	1/2/2021	12/31/2022	12/30/2023	12/28/2024	1/3/2026
DEI Shares Outstanding	-	-	-	-	-	208,911,383.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	208,911,383.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	1.08
Growth Metrics	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	27	-2.44	-450	5.65	-301	540
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	0.49%	-26.03%	36.11%
Earnings before Interest and Taxes (EBIT)	22	31	-557	14	161	250
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	43	56	-510	33	177	266
Valuation Ratios	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	2.83	-413	158	-262	0.00
Efficiency Ratios	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	1,306	1,301	1,265	1,112	1,073	1,301
Increase / (Decrease) in Invested Capital	0.00	-5.27	-36	-153	-39	0.00
Book Value per Share	$1.94	$1.88	($0.03)	($0.68)	($0.64)	$0.93
Tangible Book Value per Share	($8.22)	($7.98)	($6.79)	($6.70)	($6.56)	($4.88)
Total Capital	1,441	1,438	1,284	1,156	1,157	1,494
Total Debt	1,176	1,173	1,290	1,286	1,281	1,300
Total Long-Term Debt	1,163	1,163	1,281	1,276	1,272	1,287
Net Debt	1,039	1,036	1,271	1,242	1,197	1,107
Capital Expenditures (CapEx)	17	15	12	6.12	6.32	7.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-44	-47	-67	-75	-85	-44
Debt-free Net Working Capital (DFNWC)	93	90	-48	-31	-0.30	149
Net Working Capital (NWC)	80	80	-57	-40	-9.50	136
Net Nonoperating Expense (NNE)	104	55	212	140	-290	315
Net Nonoperating Obligations (NNO)	1,041	1,036	1,271	1,242	1,197	1,107
Total Depreciation and Amortization (D&A)	21	25	47	19	16	16
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($0.71)	($0.06)	$1.11
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	189.96M	192.89M	203.53M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.71)	($0.06)	$1.05
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	189.96M	192.89M	214.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	192.38M	195.09M	217.51M
Normalized Net Operating Profit after Tax (NOPAT)	43	57	23	80	99	182
Debt Service Ratios	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Aveanna Healthcare's official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	4/4/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	217,510,046.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	217,510,046.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.19
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.54%	7.90%	6.14%	5.20%	7.00%	6.49%	8.57%	13.98%	16.75%	22.18%	15.86%
EBITDA Growth	114.25%	-165.68%	100.01%	239.32%	-34.57%	134.54%	689,300.00%	12.00%	77.20%	267.03%	51.18%
EBIT Growth	113.88%	-224.60%	103.90%	652.80%	-30.58%	118.99%	708.37%	12.95%	83.95%	353.57%	56.36%
NOPAT Growth	112.12%	-1,093.85%	114.33%	-1,488.55%	235.12%	144.56%	141.82%	115.46%	-62.23%	135.83%	142.21%
Net Income Growth	105.40%	-521.39%	89.18%	65.09%	-45.68%	58.16%	213.38%	146.48%	94.34%	132.83%	702.10%
EPS Growth	105.08%	-515.38%	89.84%	64.71%	-46.15%	59.26%	215.38%	150.00%	85.71%	127.27%	533.33%
Operating Cash Flow Growth	47.10%	35.43%	92.53%	-259.73%	117.20%	2.42%	546.12%	27.90%	2,750.69%	12.95%	150.38%
Free Cash Flow Firm Growth	182.80%	1,476.76%	262.22%	-108.01%	23.25%	-57.20%	-48.86%	162.99%	-100.17%	-145.93%	-602.39%
Invested Capital Growth	-12.40%	-21.67%	-12.08%	-9.29%	-10.91%	-7.87%	-3.51%	-0.67%	4.43%	10.12%	20.73%
Revenue Q/Q Growth	1.19%	1.29%	0.17%	2.47%	2.92%	0.81%	2.13%	7.57%	5.42%	5.49%	0.00%
EBITDA Q/Q Growth	317.28%	-171.97%	100.02%	78.36%	-19.54%	-62.01%	338.75%	-26.62%	66.70%	-31.61%	0.00%
EBIT Q/Q Growth	1,049.53%	-199.28%	112.89%	411.66%	6.00%	-72.84%	448.81%	-28.50%	72.62%	-33.04%	0.00%
NOPAT Q/Q Growth	213.57%	-238.04%	138.37%	-936.13%	175.68%	-81.64%	108.20%	-46.54%	84.86%	14.62%	0.00%
Net Income Q/Q Growth	180.00%	-499.97%	74.86%	56.59%	224.47%	-408.09%	168.11%	-82.20%	420.41%	-47.96%	0.00%
EPS Q/Q Growth	176.47%	-515.38%	75.93%	53.85%	216.67%	-414.29%	168.18%	-80.00%	333.33%	-53.85%	0.00%
Operating Cash Flow Q/Q Growth	-240.33%	372.87%	-110.47%	-298.40%	115.11%	1,524.88%	-54.39%	-164.39%	697.42%	-35.62%	0.00%
Free Cash Flow Firm Q/Q Growth	-68.05%	25.71%	-36.26%	-131.28%	591.75%	-56.34%	-23.83%	-61.48%	-101.31%	-11,893.16%	0.00%
Invested Capital Q/Q Growth	-0.69%	-6.21%	-5.39%	2.93%	-2.45%	-3.01%	-0.91%	5.96%	2.55%	2.27%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	32.90%	30.81%	31.00%	29.73%	31.34%	31.37%	33.03%	32.82%	35.76%	32.61%	31.71%
EBITDA Margin	13.39%	-9.52%	0.00%	10.48%	8.19%	3.09%	13.26%	9.05%	14.30%	9.27%	11.80%
Operating Margin	7.94%	-15.97%	6.12%	4.66%	7.35%	6.68%	8.80%	9.26%	13.58%	8.62%	10.70%
EBIT Margin	13.28%	-13.01%	1.67%	8.36%	8.61%	2.32%	12.47%	8.29%	13.57%	8.62%	11.19%
Profit (Net Income) Margin	5.42%	-21.42%	-5.37%	-2.28%	2.75%	-8.42%	5.61%	0.93%	4.58%	2.26%	6.43%
Tax Burden Percent	103.27%	100.62%	81.46%	-749.80%	349.48%	156.75%	108.33%	51.17%	61.23%	104.82%	92.61%
Interest Burden Percent	39.56%	163.57%	-393.95%	3.63%	9.15%	-231.37%	41.55%	21.89%	55.16%	25.04%	62.06%
Effective Tax Rate	-3.27%	0.00%	0.00%	849.80%	-249.48%	0.00%	-8.33%	48.83%	38.77%	-4.82%	7.39%
Return on Invested Capital (ROIC)	11.20%	-15.61%	6.83%	-55.74%	42.34%	8.22%	17.67%	8.70%	15.86%	18.18%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	10.15%	-19.44%	3.15%	-43.31%	33.06%	2.93%	16.00%	7.00%	14.04%	14.71%	0.00%
Return on Net Nonoperating Assets (RNNOA)	130.70%	-406.13%	-58.22%	648.79%	-656.23%	-28.17%	-154.13%	-74.60%	-258.73%	-241.95%	0.00%
Return on Equity (ROE)	141.90%	-421.73%	-51.39%	593.05%	-613.89%	-19.95%	-136.45%	-65.90%	-242.87%	-223.77%	0.00%
Cash Return on Invested Capital (CROIC)	5.68%	12.50%	13.33%	10.52%	12.30%	15.84%	-24.00%	6.52%	2.05%	6.57%	-18.78%
Operating Return on Assets (OROA)	13.33%	-13.40%	1.91%	9.52%	9.88%	2.79%	15.41%	10.50%	17.21%	11.42%	0.00%
Return on Assets (ROA)	5.45%	-22.05%	-6.13%	-2.59%	3.16%	-10.12%	6.94%	1.18%	5.81%	3.00%	0.00%
Return on Common Equity (ROCE)	141.90%	-421.73%	-51.39%	593.05%	-613.89%	-19.95%	-136.45%	-65.90%	-242.87%	-223.77%	0.00%
Return on Equity Simple (ROE_SIMPLE)	3,263.77%	327.84%	0.00%	83.43%	105.40%	42.09%	0.00%	-5.43%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	39	-53	21	-171	130	24	50	27	49	56	64
NOPAT Margin	8.20%	-11.18%	4.28%	-34.94%	25.70%	4.68%	9.54%	4.74%	8.31%	9.03%	9.91%
Net Nonoperating Expense Percent (NNEP)	1.05%	3.83%	3.68%	-12.43%	9.28%	5.29%	1.67%	1.69%	1.82%	3.48%	1.90%
Return On Investment Capital (ROIC_SIMPLE)	-	-	1.77%	-	-	-	4.28%	2.19%	3.87%	4.20%	4.11%
Cost of Revenue to Revenue	67.10%	69.19%	69.00%	70.27%	68.66%	68.63%	66.97%	67.18%	64.24%	67.39%	68.29%
SG&A Expenses to Revenue	19.34%	19.04%	18.17%	17.92%	17.42%	17.32%	17.07%	16.34%	15.28%	15.34%	14.78%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	24.95%	46.78%	24.88%	25.07%	23.99%	24.69%	24.23%	23.56%	22.18%	24.00%	21.01%
Earnings before Interest and Taxes (EBIT)	63	-62	8.02	41	43	12	65	46	80	54	72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	63	-45	0.01	51	41	16	69	51	84	58	76
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.02	5.78
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.17	0.12	0.27	0.25	0.27	0.50	0.44	0.50	0.45	0.80	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	192.73	52.78	24.22	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.52%	1.89%	4.13%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.26	1.28	1.58	1.54	1.58	2.07	1.95	2.01	1.85	2.53	1.84
Enterprise Value to Revenue (EV/Rev)	0.86	0.81	0.92	0.92	0.90	1.13	1.04	1.09	0.99	1.31	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	53.31	20.59	27.78	17.93	11.82	12.50	9.82	11.51	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	125.89	35.55	58.22	21.45	13.01	13.72	10.63	12.30	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	310.20	189.05	195.12	25.93	0.00	34.20	29.61	16.33	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	77.31	549.10	113.73	137.94	64.25	63.51	25.16	33.63	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	20.63	9.02	11.07	13.90	12.12	12.52	0.00	30.70	92.12	40.28	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-191.18	-12.58	-9.92	-9.71	-10.79	-8.42	-10.37	-13.07	-106.63	144.72	5.51
Long-Term Debt to Equity	-189.81	-12.49	-9.85	-9.64	-10.71	-8.36	-10.29	-12.98	-105.86	143.28	5.45
Financial Leverage	12.88	20.89	-18.49	-14.98	-19.85	-9.61	-9.63	-10.65	-18.43	-16.45	16.94
Leverage Ratio	18.87	29.68	-24.47	-19.60	-27.09	-12.58	-12.94	-13.97	-26.23	-23.46	26.32
Compound Leverage Factor	7.47	48.55	96.39	-0.71	-2.48	29.12	-5.38	-3.06	-14.47	-5.87	16.33
Debt to Total Capital	100.53%	108.64%	111.21%	111.48%	110.22%	113.47%	110.68%	108.29%	100.95%	99.31%	84.63%
Short-Term Debt to Total Capital	0.72%	0.75%	0.80%	0.77%	0.79%	0.79%	0.80%	0.76%	0.73%	0.99%	0.85%
Long-Term Debt to Total Capital	99.81%	107.89%	110.41%	110.70%	109.43%	112.68%	109.88%	107.52%	100.22%	98.32%	83.78%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-0.53%	-8.64%	-11.21%	-11.48%	-10.22%	-13.47%	-10.68%	-8.29%	-0.95%	0.69%	15.37%
Debt to EBITDA	-28.01	-8.27	39.10	15.49	20.18	10.56	7.22	7.16	5.82	5.08	0.00
Net Debt to EBITDA	-27.40	-7.97	37.76	14.99	19.43	9.93	6.74	6.77	5.36	4.52	0.00
Long-Term Debt to EBITDA	-27.81	-8.21	38.82	15.38	20.03	10.49	7.17	7.11	5.78	5.03	0.00
Debt to NOPAT	-12.73	-8.42	227.51	142.17	141.74	15.27	-4.25	19.59	17.55	7.21	0.00
Net Debt to NOPAT	-12.45	-8.11	219.74	137.59	136.47	14.36	-3.97	18.52	16.17	6.42	0.00
Long-Term Debt to NOPAT	-12.64	-8.36	225.89	141.18	140.72	15.16	-4.22	19.45	17.42	7.14	0.00
Altman Z-Score	0.24	-0.09	0.15	0.20	0.27	0.34	0.48	0.56	0.67	1.00	-0.08
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.85	0.87	0.89	0.88	0.94	0.94	0.98	1.05	1.09	1.23	1.47
Quick Ratio	0.75	0.78	0.79	0.79	0.82	0.85	0.87	0.94	1.01	1.12	1.34
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	216	272	173	-54	266	116	89	34	-0.45	-53	-171
Operating Cash Flow to CapEx	-809.70%	2,546.58%	-191.65%	-915.29%	142.55%	1,328.24%	876.78%	-367.63%	4,567.67%	1,644.38%	95.44%
Free Cash Flow to Firm to Interest Expense	5.69	6.86	4.36	-1.37	6.73	2.96	2.33	0.94	-0.01	-1.30	-5.88
Operating Cash Flow to Interest Expense	-0.28	0.72	-0.08	-0.30	0.05	0.75	0.35	-0.24	1.43	0.81	0.15
Operating Cash Flow Less CapEx to Interest Expense	-0.31	0.70	-0.12	-0.34	0.01	0.69	0.31	-0.30	1.40	0.76	-0.01
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.00	1.03	1.14	1.14	1.15	1.20	1.24	1.27	1.27	1.33	0.00
Accounts Receivable Turnover	7.58	8.21	8.28	7.69	7.65	7.92	8.07	7.58	7.39	7.92	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	77.44	79.61	87.54	93.92	99.94	99.08	106.77	109.19	117.34	129.29	0.00
Accounts Payable Turnover	27.66	30.22	34.77	30.85	34.88	34.96	41.73	38.55	33.88	44.10	0.00
Days Sales Outstanding (DSO)	48.15	44.46	44.08	47.48	47.71	46.11	45.23	48.16	49.38	46.07	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	13.20	12.08	10.50	11.83	10.46	10.44	8.75	9.47	10.77	8.28	0.00
Cash Conversion Cycle (CCC)	34.95	32.38	33.59	35.65	37.24	35.67	36.48	38.69	38.61	37.80	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,253	1,175	1,112	1,145	1,117	1,083	1,073	1,137	1,166	1,192	1,373
Invested Capital Turnover	1.37	1.40	1.59	1.60	1.65	1.76	1.85	1.83	1.91	2.01	0.00
Increase / (Decrease) in Invested Capital	-177	-325	-153	-117	-137	-93	-39	-7.62	49	110	236
Enterprise Value (EV)	1,574	1,508	1,753	1,760	1,766	2,238	2,097	2,285	2,157	3,011	2,520
Market Capitalization	314	227	511	479	531	999	900	1,048	979	1,828	1,388
Book Value per Share	($0.04)	($0.56)	($0.68)	($0.71)	($0.62)	($0.81)	($0.64)	($0.51)	($0.06)	$0.04	$1.10
Tangible Book Value per Share	($6.80)	($6.59)	($6.70)	($6.68)	($6.58)	($6.73)	($6.56)	($6.38)	($6.28)	($5.75)	($4.47)
Total Capital	1,281	1,224	1,156	1,187	1,164	1,161	1,157	1,208	1,267	1,338	1,562
Total Debt	1,288	1,329	1,286	1,323	1,283	1,318	1,281	1,309	1,279	1,329	1,322
Total Long-Term Debt	1,279	1,320	1,276	1,314	1,274	1,309	1,272	1,299	1,269	1,316	1,309
Net Debt	1,260	1,281	1,242	1,281	1,235	1,239	1,197	1,237	1,178	1,183	1,133
Capital Expenditures (CapEx)	1.30	1.13	1.57	1.31	1.27	2.21	1.53	2.35	1.13	2.02	4.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-73	-85	-75	-79	-64	-94	-85	-43	-56	-40	8.85
Debt-free Net Working Capital (DFNWC)	-45	-37	-31	-37	-16	-15	-0.30	29	45	106	198
Net Working Capital (NWC)	-54	-46	-40	-46	-25	-25	-9.50	19	36	93	185
Net Nonoperating Expense (NNE)	13	49	46	-160	116	67	20	21	22	42	23
Net Nonoperating Obligations (NNO)	1,260	1,281	1,242	1,281	1,235	1,239	1,197	1,237	1,178	1,183	1,133
Total Depreciation and Amortization (D&A)	0.55	17	-8.01	10	-2.14	3.90	4.11	4.24	4.32	4.09	4.01
Debt-free, Cash-free Net Working Capital to Revenue	-3.99%	-4.56%	-3.94%	-4.13%	-3.26%	-4.74%	-4.18%	-2.05%	-2.56%	-1.73%	0.00%
Debt-free Net Working Capital to Revenue	-2.46%	-1.97%	-1.62%	-1.91%	-0.82%	-0.78%	-0.01%	1.36%	2.06%	4.63%	0.00%
Net Working Capital to Revenue	-2.96%	-2.47%	-2.10%	-2.39%	-1.29%	-1.24%	-0.47%	0.92%	1.64%	4.06%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.14	($0.54)	($0.14)	($0.06)	$0.07	($0.22)	$0.15	$0.03	$0.13	$0.07	$0.19
Adjusted Weighted Average Basic Shares Outstanding	189.07M	189.14M	189.96M	192.24M	192.60M	193.36M	192.89M	194.67M	200.97M	208.95M	214.60M
Adjusted Diluted Earnings per Share	$0.13	($0.54)	($0.13)	($0.06)	$0.07	($0.22)	$0.15	$0.03	$0.13	$0.06	$0.19
Adjusted Weighted Average Diluted Shares Outstanding	189.74M	189.14M	189.96M	192.24M	196.87M	193.36M	192.89M	206.24M	210.44M	222.23M	222.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	190.43M	190.73M	192.38M	192.38M	193.23M	193.23M	195.09M	195.09M	208.90M	208.91M	217.76M
Normalized Net Operating Profit after Tax (NOPAT)	26	20	21	16	26	24	33	27	51	37	67
Normalized NOPAT Margin	5.56%	4.28%	4.28%	3.26%	5.15%	4.70%	6.34%	4.75%	8.67%	5.90%	10.35%
Pre Tax Income Margin	5.25%	-21.29%	-6.60%	0.30%	0.79%	-5.37%	5.18%	1.81%	7.49%	2.16%	6.94%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.65	-1.57	0.20	1.04	1.10	0.30	1.70	1.28	2.22	1.31	2.49
NOPAT to Interest Expense	1.02	-1.35	0.52	-4.32	3.28	0.61	1.30	0.73	1.36	1.37	2.20
EBIT Less CapEx to Interest Expense	1.62	-1.60	0.16	1.00	1.07	0.24	1.66	1.21	2.19	1.26	2.33
NOPAT Less CapEx to Interest Expense	0.99	-1.38	0.48	-4.36	3.24	0.55	1.26	0.66	1.33	1.32	2.05
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Aveanna Healthcare (AVAH) has shown notable revenue growth and improving cash generation over the last few years, but earnings have remained volatile due to one-time items and a high debt load. Below is a concise, data-driven snapshot of trends from AVAH’s quarterly statements in the last four years, focusing on the most recent quarters to provide context for near-term investors.

Revenue growth: Quarterly operating revenue rose from the low-to-mid $400s million in 2022 to about $622 million in Q3 2025, marking a meaningful uplift over the four-year window.
Net income turning positive in 2025: After multiple years of losses in several quarters, AVAH reported positive net income in Q2 2025 ($27.0 million) and Q3 2025 ($14.1 million), with a string of other recent quarters also showing profitability before other adjustments.
Operating cash flow strength: Net cash from continuing operating activities was solid in 2025, notably about $51.6 million in Q2 2025 and $33.2 million in Q3 2025, signaling healthy cash generation from core operations.
Free cash flow (approximate) improving: With capex in the low single-digit millions per quarter, near-term free cash flow has been positive in recent 2024–2025 quarters (for example, around $50 million in Q2 2025 and about $31 million in Q3 2025).
Margin signals: In Q3 2025, gross margin was around 32–33% (about $203 million gross profit on $622 million revenue), and operating margin approached mid-single digits, indicating improving profitability despite a challenging path earlier in the cycle.
Debt management activity: Long-term debt remained high but was actively managed in 2025, with substantial debt issuance offset by large repayments, resulting in a net positive financing cash flow and a net cash increase for the period.
Liquidity indicators: Cash & equivalents were meaningful (roughly $146 million in Q3 2025), with total assets around $1.8 billion and total liabilities at a similar scale, suggesting existing liquidity to support near-term needs.
Capital-light model: Quarterly capex has been relatively modest (low single-digit millions), supporting a greater share of cash flow remaining available to repay debt or fund growth initiatives.
Earnings per share (EPS) improvement: Basic EPS in Q3 2025 was $0.07 and diluted EPS $0.06, reflecting a move toward profitability on a per-share basis in the most recent quarter.
One-time and restructuring items: Periods have included non-cash adjustments, impairment charges, and restructuring costs (for example, impairment charges in 2023 and various non-cash and restructuring items across quarters). These items have contributed to earnings volatility but are not ongoing operating cash expenses.

Balance sheet dynamics: Total liabilities have been substantial and, in some periods, total equity has been modest or variable due to restatements and large non-cash items. While 2025-Q3 shows a positive near-term net equity position, the path there has included volatility tied to accounting adjustments.
Debt load and interest burden: AVAH carries a large debt load (long-term debt in the $1.27–1.29 billion range across 2024–2025) and still incurs meaningful interest expense in quarterly results, which can cap net income during softer revenue periods.
Earnings volatility: The company has experienced quarters with negative net income (notably 2023 and 2024), driven by impairment and restructuring costs, which investors should consider when valuing earnings stability.
Leveraged funding tailwinds: While debt issuance and repayments indicate active balance-sheet management, the reliance on debt financing and refinancing introduces ongoing financing risk that investors should monitor through future filings.

05/26/26 11:39 PM ETAI Generated. May Contain Errors.

Aveanna Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aveanna Healthcare's financial year ends in January. Their financial year 2026 ended on January 3, 2026.

Aveanna Healthcare's net income appears to be on a downward trend, with a most recent value of $225.03 million in 2026, falling from -$76.52 million in 2020. The previous period was -$10.93 million in 2024. View Aveanna Healthcare's forecast to see where analysts expect Aveanna Healthcare to go next.

Aveanna Healthcare's total operating income in 2026 was $256.46 million, based on the following breakdown:

Total Gross Profit: $810.48 million
Total Operating Expenses: $554.02 million

Over the last 5 years, Aveanna Healthcare's total revenue changed from $1.38 billion in 2020 to $2.43 billion in 2026, a change of 75.8%.

Aveanna Healthcare's total liabilities were at $1.82 billion at the end of 2026, a 1.8% increase from 2024, and a 15.2% increase since 2020.

In the past 5 years, Aveanna Healthcare's cash and equivalents has ranged from $19.22 million in 2022 to $193.26 million in 2026, and is currently $193.26 million as of their latest financial filing in 2026.

Over the last 5 years, Aveanna Healthcare's book value per share changed from 1.94 in 2020 to 0.93 in 2026, a change of -51.9%.

Related Companies

Financial statements for NASDAQ:AVAH last updated on 5/17/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aveanna Healthcare (AVAH) Financials

Financials Breakdown Chart

Key Financial Trends

Aveanna Healthcare Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aveanna Healthcare (AVAH) Financials

Annual Income Statements for Aveanna Healthcare

Quarterly Income Statements for Aveanna Healthcare

Annual Cash Flow Statements for Aveanna Healthcare

Quarterly Cash Flow Statements for Aveanna Healthcare

Annual Balance Sheets for Aveanna Healthcare

Quarterly Balance Sheets for Aveanna Healthcare

Annual Metrics And Ratios for Aveanna Healthcare

Quarterly Metrics And Ratios for Aveanna Healthcare

Financials Breakdown Chart

Key Financial Trends

Aveanna Healthcare Financials - Frequently Asked Questions

When does Aveanna Healthcare's fiscal year end?

How has Aveanna Healthcare's net income changed over the last 5 years?

What is Aveanna Healthcare's operating income?

How has Aveanna Healthcare's revenue changed over the last 5 years?

How much debt does Aveanna Healthcare have?

How much cash does Aveanna Healthcare have?

How has Aveanna Healthcare's book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools